[1]
|
Bombardieri E, Seregni E, Villano C, et al. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging, 2004, 48(2):150-163. |
[2]
|
Mottaghy FM, Reske SN. Functional imaging of neuroendocrine tumours with PET. Pituitary, 2006, 9(3):237-242. |
[3]
|
Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors:a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med, 2010, 51(5):704-712. |
[4]
|
Jacob T, Grahek D, Younsi N, et al. Positron emission tomography with [18F] FDOPA and [18F] FDG in the imaging of small cell lung carcinoma:preliminary results. Eur J Nucl Med Mol Imaging, 2003, 30(9):1266-1269. doi: 10.1007/s00259-003-1249-3 |
[5]
|
Orlefors H, Sundin A, Lu L, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging, 2006, 33(1):60-65. doi: 10.1007/s00259-005-1891-z |
[6]
|
Koopmans KP, de Vries EG, Kema IP, et al. Staging of carcinoid tumours with 18F-DOPA PET:a prospective, diagnostic accuracy study. Lancet Oncol, 2006, 7(9):728-734. doi: 10.1016/S1470-2045(06)70801-4 |
[7]
|
Becherer A, Szabó M, Karanikas G, et al. Imaging of advanced neuroendocrine tumors with 18F-FDOPA PET. J Nucl Med, 2004, 45(7):1161-1167. |
[8]
|
Montravers F, Grahek D, Kerrou K, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. J Nucl Med, 2006, 47(9):1455-1462. |
[9]
|
Ambrosini V, Tomassetti P, Rubello D, et al. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. Nucl Med Commun, 2007, 28(6):473-477. |
[10]
|
Lenders JW, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet, 2005, 366(9486):665-675. doi: 10.1016/S0140-6736(05)67139-5 |
[11]
|
Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology:role in the management of neural crest tumours. Eur J Nucl Med, 1994, 21(6):561-581. |
[12]
|
Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas:detection with 18F DOPA whole body PET—initial results. Radiology, 2002, 222(2):507-512. |
[13]
|
Hoegerle S, Ghanem N, Altehoefer C, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging, 2003, 30(5):689-694. doi: 10.1007/s00259-003-1115-3 |
[14]
|
Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus[131I]-metaiodobenzylguanidine scintigra-phy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab, 2003, 88(9):4083-4087. doi: 10.1210/jc.2003-030235 |
[15]
|
Pacak K, Eisenhofer G, Carrasquilllo JA, et al. 6-[18F]fluorodopamine positron emission tomographic(PET) scanning for diagnostic localization of pheochromocytoma. Hypertension, 2001, 36(1):6-8. |
[16]
|
Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med, 2001, 28(1):64-71. |
[17]
|
Hardy OT, Hernandez-Pampaloni M, Saffer JR, et al. Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr, 2007, 150(2):140-145. doi: 10.1016/j.jpeds.2006.08.028 |
[18]
|
Kauhanen S, Seppänen M, Minn H, et al. Fluorine-18-L-dihydroxyphenylalanine(18F-DOPA)positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab, 2007, 92(4):1237-1244. doi: 10.1210/jc.2006-1479 |
[19]
|
Hofland LJ, Lamberts SW, van Hagen PM, et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1] octreotide in somatostatin receptor-positive organs. J Nucl Med, 2003, 44(8):1315-1321. |
[20]
|
Kaltsas G, Rockall A, Papadogias D, et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol, 2004, 151(1):15-27. |
[21]
|
Hofmann M, Maecke H, Börner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC:preliminary data. Eur J Nucl Med, 2001, 28(12):1751-1757. doi: 10.1007/s002590100639 |
[22]
|
Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using[68Ga]-DOTA-D-Phe1-Tyr3-octreotide in comparison to[111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol, 2003, 5(1):42-48. |
[23]
|
Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:comparison with somatostatin receptor scintigraphy and CT. J Nucl Med, 2007, 48(4):508-518. |
[24]
|
Campana D, Ambrosini V, Pezzilli R, et al. Standardized uptake values of 68Ga-DOTANOC PET:a promising prognostic tool in neuroendocrine tumors. J Nucl Med, 2010, 51(3):353-359. |
[25]
|
Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med, 2010, 51(5):669-673. |
[26]
|
Hofmann M, Maecke H, Börner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC:preliminary data. Eur J Nucl Med, 2001, 28(12):1751-1757. doi: 10.1007/s002590100639 |
[27]
|
Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:comparison with somatostatin receptor scintigraphy and CT. J Nucl Med, 2007, 48(4):508-518. |
[28]
|
Poeppel TD, Binse I, Petersenn S, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med, 2011, 52(12):1864-1870. doi: 10.2967/jnumed.111.091165 |
[29]
|
Forrer F, Uusijärvi H, Waldherr C, et al. A comparison of 111In-DOTATOC and 111In-DOTATATE:biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging, 2004, 31(9):1257-1262. |
[30]
|
Haug AR, Auernhammer CJ, Wängler B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med, 2010, 51(9):1349-1356. doi: 10.2967/jnumed.110.075002 |
[31]
|
Kayani I, Conry BG, Groves AM, et al. A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors. J Nucl Med, 2009, 50(12):1927-1932. doi: 10.2967/jnumed.109.066639 |